1192 HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS

1191 LOW RATE OF ON-TREATMENT RESISTANCE TO DANOPREVIR BOOSTED BY RITONAVIR (DNVR) COMBINED WITH PEG-IFNa-2A/RIBAVIRIN: 12 WEEK INTERIM ANALYSIS FROM DAUPHINE STUDY S. Le Pogam, M. Navarro, L. Bu, A. Voulgari, M. Illnicka, J.M. Yan, K. Klumpp, I. Najera. Virology Discovery, Hoffmann-La Roche, Nutley, NJ, Biostatistics, Genentech, South San Francisco, CA, USA; Biostatistics, Roche Pharma Development in Asia Pacific, Shanghai, China; Clinical Development, Roche Products Ltd, Welwyn, UK; Discovery Technologies, Hoffmann-La Roche, Nutley, NJ, USA E-mail: sophie.le_pogam@roche.com